Eli Lilly | LLY - Selling And Administration Expenses


Eli Lilly reported $2.93B in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.58B 316M Mar/2026
Abbott USD 3.27B 138M Mar/2026
ALKERMES USD 264.59M 77.4M Mar/2026
Amgen USD 1.58B 354M Mar/2026
AstraZeneca USD 5.06B 455M Mar/2026
Baxter International USD 728M 33M Mar/2026
Biogen USD 554.3M 128.2M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Coherus Biosciences USD 15M 6.26M Dec/2025
Drreddys Laboratories INR 26.92B 3.74B Dec/2025
Eli Lilly USD 2.93B 198M Mar/2026
Gilead Sciences USD 1.45B 326M Mar/2026
GlaxoSmithKline GBP 2.12B 558M Mar/2026
Glaxosmithkline GBP 3.56B 650.29M Dec/2025
J&J USD 6.03B 719M Mar/2026
Medtronic 2.96B 9M Dec/2025
Merck USD 2.67B 180M Mar/2026
Neurocrine Biosciences USD 318.5M 16.7M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Novartis USD 3.44B 132M Dec/2025
Novo Nordisk DKK 13.22B 4.22B Mar/2026
Perrigo USD 267.3M 11.4M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
Phibro Animal Health USD 78.32M 10.24M Dec/2025
Prestige Brands USD 30.28M 606K Mar/2026
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.33B 419M Mar/2026
Sanofi EUR 2.75B 455M Dec/2025
United Therapeutics USD 156.6M 34M Mar/2026
Zoetis USD 588M 31M Mar/2026